
<PAGE>
                                                                    EXHIBIT 99.1

[GENITOPE CORPORATION LOGO]


                    GENITOPE CORPORATION ANNOUNCES CLOSING OF
                  $60 MILLION PRIVATE PLACEMENT OF COMMON STOCK

REDWOOD CITY, CALIF., DECEMBER 27, 2004 - GENITOPE CORPORATION (NASDAQ: GTOP), a
biotechnology company focused on the research and development of novel
immunotherapies for the treatment of cancer, has completed the sale of 4,250,000
unregistered shares of newly issued common stock at a price of $14.25 per share
to selected institutional and accredited investors, resulting in estimated net
proceeds to the Company of approximately $57.2 million. WR Hambrecht + Co, LLC
acted as placement agent for the transaction.

Genitope intends to use the net proceeds to fund costs related to leasing and
build out and qualification of a commercial scale manufacturing facility, to
fund expenses related to manufacturing and potential commercialization, clinical
trials and research, and for the establishment of sales and marketing
capabilities, as well as for general corporate purposes, including working
capital. Pending these uses, Genitope plans to invest the net proceeds in
short-term, interest-bearing obligations, investment-grade instruments,
certificates of deposit or direct or guaranteed obligations of the United
States.


ABOUT GENITOPE CORPORATION

Genitope Corporation is a biotechnology company focused on the research and
development of novel immunotherapies for the treatment of cancer. Genitope
Corporation's lead product candidate, MyVax(R)Personalized Immunotherapy, is a
patient-specific active immunotherapy based on the unique genetic makeup of a
patient's tumor and is designed to activate the patient's immune system to
identify and attack cancer cells. Genitope Corporation is conducting a pivotal
phase 3 trial using MyVax(R) Personalized Immunotherapy in previously untreated
follicular non-Hodgkin's lymphoma patients. Genitope Corporation is based in
Redwood City, California.

For more information, contact John Vuko, Vice President and Chief Financial
Officer of Genitope Corporation, 650-472-2113 or ir@genitope.com.

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS." FOR THIS PURPOSE, ANY
STATEMENTS CONTAINED IN THIS PRESS RELEASE THAT ARE NOT STATEMENTS OF HISTORICAL
FACT MAY BE DEEMED FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS ABOUT THE
ANTICIPATED NET PROCEEDS OF THE PRIVATE PLACEMENT AND THE INTENDED USE OF THOSE
NET PROCEEDS. WORDS SUCH AS "BELIEVES," "ANTICIPATES," "PLANS," "EXPECTS,"
"WILL," "INTENDS" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY
FORWARD-LOOKING STATEMENTS. THERE ARE A NUMBER OF IMPORTANT FACTORS THAT COULD
CAUSE GENITOPE CORPORATION'S RESULTS TO DIFFER MATERIALLY FROM THOSE INDICATED
BY THESE FORWARD-LOOKING STATEMENTS , INCLUDING WITHOUT LIMITATION, ECONOMIC
CONDITIONS, THE COMPANY'S NEED FOR ADDITIONAL FINANCING, INTENSE COMPETITION IN
VARIOUS ASPECTS OF ITS BUSINESS, THE RISKS OF GROWTH, ITS DEPENDENCE ON KEY
PERSONNEL, PENDING LITIGATION AND OTHER RISKS DETAILED IN GENITOPE CORPORATION'S
FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE QUARTERLY
REPORT FOR THE FISCAL QUARTER ENDED SEPTEMBER 30, 2004. YOU ARE CAUTIONED NOT TO
PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF
THE DATE OF THIS PRESS RELEASE. GENITOPE CORPORATION UNDERTAKES NO OBLIGATION TO
REVISE OR UPDATE ANY FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR
CIRCUMSTANCES AFTER THE DATE HEREOF.

